Trump ad­min­is­tra­tion opens the door to low­er drug prices as Medicare Ad­van­tage plans are pushed to step ther­a­py ap­proach

The Trump ad­min­is­tra­tion has tak­en an­oth­er step to­wards low­er­ing drug costs for con­sumers, this time aim­ing at the mil­lions of mem­bers in Medicare Ad­van­tage plans.

Un­der new rules an­nounced late Tues­day, the ad­min­is­tra­tion is giv­ing these plans the right to set up what’s called step ther­a­py plans for physi­cian-ad­min­is­tered and oth­er Part B drugs. These plans, com­mon­ly used among pri­vate in­sur­ers, man­date that mem­bers use the least ex­pen­sive drugs avail­able for their con­di­tions be­fore mov­ing on to prici­er ther­a­pies if need­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.